Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
April 2019
-
Press release
Novartis updates on the migraine collaboration with Amgen
Basel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of… -
In The News
Medicines and transformative effect
In this Bloomberg interview, Vas Narasimhan, CEO of Novartis shares his thoughts on how medicines can have a transformative effect. -
Press release
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one… -
Featured News
Sustaining the momentum toward universal health coverage in Africa
The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019. -
Press release
Novartis first-in-class Cosentyx® approved in China for psoriasis patients
China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is… -
Press release
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy … -
Press release
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
Acquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3…
March 2019
-
Ad hoc release
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients… -
Story From Our Labs
What goes wrong with the window to the soul in glaucoma?
Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
-
Ad hoc release
Novartis plans for Alcon spin-off on April 9, 2019
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange… -
Story Discovery
Experimental gene therapy discovered in-house enters clinical testing
Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.
-
In The News
It's Time to "Pivot Towards Transformational Innovation"
In this interview with Susie Gharib from Fortune, Vas Narasimhan, CEO of Novartis, shares his perspective on changing the culture within Novartis.